Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

GB0009895292
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG000C0YDQ1
AZN
AstraZeneca PLC
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Health Care · THEMEFOLIO: $HLTH
NAME
AstraZeneca PLC
ISIN
GB0009895292
TICKER
AZN
MIC
XLON
REUTERS
AZN.L
BLOOMBERG
AZN LN
Thu, 09.10.2025       AstraZeneca
GB0009895292

LONDON, UK and BUDAPEST, HUNGARY, Oct. 9, 2025 /PRNewswire/ -- Turbine, a leading company specializing in virtualizing biological experiments with AI, today announced a collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) to test the ability of Turbine's platform to rationalize antibody-drug conjugate (ADC) disco...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Tue, 07.10.2025       AstraZeneca
US0463531089

Positive high-level results from the Bax24 Phase III trial showed baxdrostat demonstrated a statistically significant and highly clinically meaningful reduction in ambulatory 24-hour average systolic blood pressure (SBP) compared with placebo at 12 weeks. Efficacy was observed throughout the 24-hour period, including early morning, when patients w...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Mon, 06.10.2025       AstraZeneca
US0463531089

Positive high-level results from the TROPION-Breast02 Phase III trial showed DATROWAY® (datopotamab deruxtecan-dlnk) demonstrated a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) compared to investigator's choice of chemotherapy as 1st-line...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Fri, 26.09.2025       AstraZeneca
US0463531089

AstraZeneca today announces the launch of AstraZeneca Direct, an online platform designed to create a simple, convenient way for eligible patients to access their prescribed medications at a transparent cash price with home delivery. AstraZeneca Direct will support people living with chronic conditions such as asthma, diabetes, heart failure and c...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Wed, 24.09.2025       AstraZeneca
US0463531089

AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for ENHERTU® (fam-trastuzumab deruxtecan-nxki) in combination with pertuzumab has been accepted and granted Priority Review in the US for the 1st-line treatment of adult patients with unresectable or metastatic HER2-positive breast cancer. The Food and Drug Admini...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Mon, 22.09.2025       AstraZeneca
GB0009895292

BOSTON, Sept. 22, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company transforming precision medicine, today announced an expansion of its collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) from the World CB & CDx Summit in Boston. The companies aim to improve the diagnosis and treatment of breast and prostate canc...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Mon, 22.09.2025       AstraZeneca
GB0009895292

BOSTON, Sept. 22, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company transforming precision medicine, today announced an expansion of its collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) from the World CB & CDx Summit in Boston. The companies aim to improve the diagnosis and treatment of breast and prostate canc...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Mon, 22.09.2025       AstraZeneca
GB0009895292

BOSTON, Sept. 22, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company transforming precision medicine, today announced an expansion of its collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) from the World CB & CDx Summit in Boston. The companies aim to improve the diagnosis and treatment of breast and prostate canc...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Mon, 22.09.2025       AstraZeneca
GB0009895292

BOSTON, Sept. 22, 2025 /CNW/ -- SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company transforming precision medicine, today announced an expansion of its collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) from the World CB & CDx Summit in Boston. The companies aim to improve the diagnosis and treatment of breast and prostate cancer by d...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Thu, 18.09.2025       AstraZeneca
US0463531089

AIRSUPRA’s US Prescribing Information now includes clinically meaningful evidence from the BATURA study in patients with mild asthma.1 The BATURA Phase IIIb trial, which evaluated severe exacerbation risk reduction, examined the efficacy of as-needed AIRSUPRA compared to as-needed albuterol,2 the most commonly used rescue medication for asthma in...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Wed, 17.09.2025       AstraZeneca
US0463531089

Positive high-level results from a pre-specified interim analysis of the Phase III TULIP-SC trial in patients with systemic lupus erythematosus (SLE) showed that the subcutaneous (SC) administration of AstraZeneca’s SAPHNELO® (anifrolumab) demonstrated a statistically significant and clinically meaningful reduction in disease activity compared to...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Sun, 07.09.2025       AstraZeneca
US0463531089

Positive results from the final overall survival (OS) analysis of the FLAURA2 Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) with the addition of pemetrexed and platinum-based chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the key secondary endpoint of OS compared to TAGRISSO monotherap...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Sat, 30.08.2025       AstraZeneca
US0463531089

Positive full results from the ​BaxHTN Phase III trial showed ​baxdrostat demonstrated a statistically significant and clinically meaningful reduction in mean seated systolic blood pressure (SBP) at two doses (2mg and 1mg) compared with placebo at 12 weeks. Results were seen in patients with hard-to-control (uncontrolled and resistant) hypertensio...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Fri, 15.08.2025       AstraZeneca
US0463531089

AstraZeneca today launches FluMist Home, the first-of-its-kind, at-home delivery service for FLUMIST® (Influenza Vaccine Live, Intranasal). FLUMIST is the first and only seasonal influenza vaccine approved to be self-administered by adults 18 to 49 years of age or administered by a parent or caregiver to individuals 2-17 years of age.1 This press...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Wed, 13.08.2025       AstraZeneca
GB0009895292

The HBA's ACE Awards spotlight bold, people-first programs that are transforming how the industry develops, engages, and empowers its workforce. FAIRFIELD, N.J., Aug. 13, 2025 /PRNewswire/ -- The Healthcare Businesswomen's Association (HBA) today announced the recipients of its 2025 Advancement, Commitment, and Engagement (ACE) Awards, honoring h...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Thu, 07.08.2025       AstraZeneca
GB0009895292

The agreement is a critical step in ensuring adult patients living with NMOSD and gMG have public access to Ultomiris MISSISSAUGA, ON, Aug. 7, 2025 /CNW/ - Alexion Pharma Canada Corp., AstraZeneca's Rare Disease group, has entered into a Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for Ultomiris (ravulizumab) for th...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Wed, 06.08.2025       AstraZeneca
GB0009895292

Das Instrument ZEG GB0009895292 ASTRAZENECA PLC DL-,25 EQUITY wird ex Dividende/Zinsen gehandelt am 07.08.2025 The instrument ZEG GB0009895292 ASTRAZENECA PLC DL-,25 EQUITY has its ex-dividend/interest day on 07.08.2025...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Tue, 05.08.2025       AstraZeneca
GB0009895292

BOSTON and ROLLE, Switzerland, Aug. 5, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced an expansion of its partnership with AstraZeneca (LSE/STO/Nasdaq: AZN). This new, multi-year collaboration will leverage SOPHiA GENETICS's multimodal...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Tue, 05.08.2025       AstraZeneca
GB0009895292

BOSTON and ROLLE, Switzerland, Aug. 5, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced an expansion of its partnership with AstraZeneca (LSE/STO/Nasdaq: AZN). This new, multi-year collaboration will leverage SOPHiA GENETICS's multimodal...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Tue, 05.08.2025       AstraZeneca
GB0009895292

BOSTON and ROLLE, Switzerland, Aug. 5, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced an expansion of its partnership with AstraZeneca (LSE/STO/Nasdaq: AZN). This new, multi-year collaboration will leverage SOPHiA GENETICS's multimodal...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Tue, 05.08.2025       AstraZeneca
GB0009895292

BOSTON and ROLLE, Switzerland, Aug. 5, 2025 /CNW/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced an expansion of its partnership with AstraZeneca (LSE/STO/Nasdaq: AZN). This new, multi-year collaboration will leverage SOPHiA GENETICS's multimodal AI Fact...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Tue, 29.07.2025       AstraZeneca
GB0009895292

AstraZeneca: Revenue and EPS summary   H1 2025 % Change Q2 2025 % Change   $m Actual CER1 $m Actual CER - Product Sales 26,670 8 10 13,795 11 10 - Alliance Revenue 1,293 38 38 654 36 35...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Mon, 28.07.2025       AstraZeneca
US0463531089

AstraZeneca’s supplemental Biologics License Application (sBLA) for IMFINZI® (durvalumab) has been accepted and granted Priority Review in the US for the treatment of patients with resectable, early-stage and locally advanced (Stages II, III, IVA) gastric and gastroesophageal junction (GEJ) cancers. The Food and Drug Administration (FDA) grants...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Mon, 21.07.2025       AstraZeneca
US0463531089

AstraZeneca today announces $50 billion of investment in the United States by 2030, building on America’s global leadership in medicines manufacturing and R&D. This investment is expected to create tens of thousands of new, highly skilled direct and indirect jobs across the country powering growth and delivering next generation medicines for p...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Mon, 21.07.2025       AstraZeneca
US0463531089

Positive high-level results from the final overall survival (OS) analysis of the FLAURA2 Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) with the addition of pemetrexed and platinum-based chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the key secondary endpoint of OS compared to TAGRISSO...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Mon, 14.07.2025       AstraZeneca
US0463531089

Positive high-level results from the BaxHTN Phase III trial showed baxdrostat at two doses (2mg and 1mg) demonstrated a statistically significant and clinically meaningful reduction in mean seated systolic blood pressure (SBP) compared with placebo at 12 weeks. The trial also successfully met all secondary endpoints. Patients with uncontrolled or...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Tue, 24.06.2025       AstraZeneca
US0463531089

DATROWAY® (datopotamab deruxtecan-dlnk) has been approved in the US for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy. This indication is approved under accelerated approval based on objective respon...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Mon, 02.06.2025       AstraZeneca
US0463531089

Positive results from the DESTINY-Breast09 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to a taxane, trastuzumab and pertuzumab (THP) as a 1st-line treatment for patients with HER2-p...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Sun, 01.06.2025       AstraZeneca
US0463531089

Positive results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s IMFINZI® (durvalumab) in combination with standard-of-care FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-fr...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Sun, 01.06.2025       AstraZeneca
US0463531089

Positive results from the SERENA-6 Phase III trial showed that AstraZeneca’s camizestrant in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS). The trial evaluated switching...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Thu, 29.05.2025       AstraZeneca
GB0009895292

Danaher has entered a partnership with AstraZeneca to scale precision medicine, including developing the next generation of AI-powered diagnosticsThis partnership aims to create a framework for rapid diagnostics research, development and commercialization Danaher, through its Centers for Enabling Precision Medicine, will provide support in all as...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Tue, 27.05.2025       AstraZeneca
GB0009895292

Equity Insider News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, May 27, 2025 /CNW/ -- Equity Insider News Commentary – Artificial intelligence is rapidly becoming one of the most promising frontiers in healthcare innovation. Ark Invest's Cathie Wood recently pointed to breakthrough research from Mass General Brigham—where...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Tue, 27.05.2025       AstraZeneca
GB0009895292

Equity Insider News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, May 27, 2025 /PRNewswire/ -- Equity Insider News Commentary – Artificial intelligence is rapidly becoming one of the most promising frontiers in healthcare innovation. Ark Invest's Cathie Wood recently pointed to breakthrough research from Mass General Brigha...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Tue, 27.05.2025       AstraZeneca
GB0009895292

Equity Insider News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, May 27, 2025 /PRNewswire/ -- Equity Insider News Commentary – Artificial intelligence is rapidly becoming one of the most promising frontiers in healthcare innovation. Ark Invest's Cathie Wood recently pointed to breakthrough research from Mass General Brigha...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Wed, 21.05.2025       AstraZeneca
US0463531089

AstraZeneca advances its ambition to eliminate cancer as a cause of death with new data across its diverse, industry-leading portfolio and pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting, May 30 to June 3, 2025. More than 80 abstracts will feature 20 approved and potential new medicines from the Company including two p...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Mon, 19.05.2025       AstraZeneca
US0463531089

Positive full results from the BATURA Phase IIIb trial showed AstraZeneca’s anti-inflammatory reliever rescue therapy, AIRSUPRA (albuterol/budesonide), demonstrated statistically significant and clinically meaningful improvements in all primary and secondary endpoints compared to albuterol in patients with mild asthma.1,2 These data were published...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Tue, 13.05.2025       AstraZeneca
US0463531089

AstraZeneca will present the latest clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American Thoracic Society (ATS) International Conference, in San Francisco, CA from May 16 to 21, 2025. With more than 75 abstracts, including eight late-breakers, the Company continues to drive inno...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Fri, 09.05.2025       AstraZeneca
US0463531089

Positive high-level results from the POTOMAC Phase III trial showed one year of treatment with AstraZeneca’s IMFINZI® (durvalumab) plus standard-of-care BCG induction and maintenance therapy demonstrated a statistically significant and clinically meaningful improvement in disease-free survival (DFS) for patients with high-risk non-muscle-invasive...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Wed, 07.05.2025       AstraZeneca
US0463531089

Positive high-level results from the DESTINY-Breast11 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by paclitaxel, trastuzumab and pertuzumab (THP) demonstrated a statistically significant and clinically meaningful improvement in pathologic complete response (pCR) rate versus standard of care (dose-dense doxorubicin an...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Fri, 02.05.2025       AstraZeneca
US0463531089

Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca’s fixed-dose triple-combination therapy BREZTRI AEROSPHERE (budesonide/glycopyrronium/formoterol fumarate or BGF (320/28.8/9.6μg)) met all primary endpoints, demonstrating a statistically significant and clinically mea...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Tue, 29.04.2025       AstraZeneca
GB0009895292

AstraZeneca: Revenue and EPS summary   Q1 2025 % Change       $m Actual CER1       - Product Sales 12,875 6 9       - Alliance Revenue 639 40 42       Product Revenue2 13,514 7 10       Collaboration Revenue 74 64 64    ...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Mon, 28.04.2025       AstraZeneca
GB0009895292

BOSTON and ROLLE, Switzerland, April 29, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and global leader in data-driven medicine, today announced the expansion of its ongoing collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) to accelerate the deployment of MSK-ACCESS® powered with SOPHiA DDM™...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Mon, 28.04.2025       AstraZeneca
GB0009895292

BOSTON and ROLLE, Switzerland, April 28, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and global leader in data-driven medicine, today announced the expansion of its ongoing collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) to accelerate the deployment of MSK-ACCESS® powered with SOPHiA DDM™...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Mon, 28.04.2025       AstraZeneca
GB0009895292

BOSTON and ROLLE, Switzerland, April 28, 2025 /CNW/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and global leader in data-driven medicine, today announced the expansion of its ongoing collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) to accelerate the deployment of MSK-ACCESS® powered with SOPHiA DDM™ glo...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Mon, 28.04.2025       AstraZeneca
GB0009895292

BOSTON and ROLLE, Switzerland, April 28, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and global leader in data-driven medicine, today announced the expansion of its ongoing collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) to accelerate the deployment of MSK-ACCESS® powered with SOPHiA D...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Mon, 21.04.2025       AstraZeneca
US0463531089

Positive high-level results from a planned interim analysis of the DESTINY-Breast09 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) in combination with pertuzumab demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to a taxane, trastuzumab and pertuzuma...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Mon, 31.03.2025       AstraZeneca
US0463531089

Positive results from the PURSUIT Phase IIb trial for AstraZeneca’s AZD0780 demonstrated a statistically significant low-density lipoprotein cholesterol (LDL-C) reduction when administered on top of standard-of-care statin therapy, as compared with placebo.1,2 AZD0780 is an investigational once-daily oral PCSK9 inhibitor for patients currently not...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Mon, 31.03.2025       AstraZeneca
US0463531089

AstraZeneca’s IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the bladder) has been approved in the US for the treatment of adult patients with muscle-invasive bladder cancer (MIBC). The approval was granted by the...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Wed, 26.03.2025       AstraZeneca
US0463531089

New study results presented at the European Lung Cancer Congress (ELCC) 2025, March 26 to 29, demonstrate the role of AstraZeneca’s TAGRISSO® (osimertinib), as monotherapy and as the backbone for novel combinations, across stages and settings of epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). Highlights include...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink
Mon, 17.03.2025       AstraZeneca
GB0009895292

CAMBRIDGE, United Kingdom, March 17, 2025 /PRNewswire/ -- IgniteData has announced a collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) and Cambridge University Hospitals NHS Foundation Trust (CUH) to launch its Archer tool for clinical data integration in an ongoing Phase 3 study sponsored by AstraZeneca. This collaboration marks a significant...
Read more
AstraZeneca
Technical Analysis Termsheets Terminal
Permalink